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OBJECTIVE — To assess the effect of an Internet-based glucose monitoring system (IBGMS)
on A1C levels in patients with type 2 diabetes treated with insulin.
RESEARCH DESIGN AND METHODS — This trial involved 50 patients randomly
assigned to receive either conventional treatment alone or with additional follow-up through an
IBGMS for 6 months. Patients randomized to the intervention group uploaded blood glucose
readings every 2 weeks to a secure Web site for review and receipt of feedback from their
endocrinologist. A1C and laboratory test results were collected at 0, 3, and 6 months.
RESULTS — Thebaselineparameterswerenotsigniﬁcantlydifferent.Overa6-monthfollow-
up, A1C dropped from 8.8 to 7.6% (P  0.001) in the intervention group compared with 8.5 to
8.4% (P  0.51) in the control group.
CONCLUSIONS — The use of IBGMS signiﬁcantly improved A1C levels in patients with
type 2 diabetes treated with insulin.
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I
n the management of diabetes, self-
monitoringofbloodglucose(SMBG)is
performed as an adjunct to A1C mea-
surements in order to assess and modify
treatment (1–3); however, it often re-
quireshealthcareprofessionalstohelpin-
terpret the results to reﬁne treatment (4–
6). The Internet provides a readily
accessible platform for communication
and remote health monitoring (7). In this
study, we evaluated whether the use of an
IBGMS would improve the outcome of
treatment for patients with type 2
diabetes.
RESEARCH DESIGN AND
METHODS— We enrolled 50 type 2
diabetic patients being treated with insu-
linaloneorincombinationwithoralanti-
hyperglycemic medications. Inclusion
criteria were a recent A1C 7.0%, Inter-
net access, and prior training in SMBG.
Patients were randomly assigned to either
of the groups using a computer random
number generator. All patients were pro-
vided with a meter and test strips for test-
ing at least three times daily and were
asked to perform a laboratory blood test
and visit their endocrinologist every 3
months. Patients randomized to the con-
trol group were asked to keep a diary of
SMBG for every visit to their endocrinol-
ogist. Patients randomized to the inter-
vention group were asked to upload their
SMBG readings every 2 weeks to a secure
Web site (ALR Technologies, Atlanta,
GA). These data were presented in table
andgraphformatsaccordingtothetime
of day, and automatic calculations were
done to show the average, standard de-
viation, and range for speciﬁc time pe-
riods. The system allowed the patient to
input medications, set alarms, view a
summary of readings, and send a mes-
sage to their endocrinologist who then
viewed the readings and sent feedback.
The endocrinologist’s recommenda-
tions included changes in insulin dos-
age, suggestions on testing frequency,
and giving compliments.
Baseline demographical data were
collected from patient charts. A1C values
were measured using the ADVIA Centaur
Immunoassay System (Tarrytown, NY).
Data were analyzed using a computerized
database (Excel, Microsoft) and the SAS
statistical software (SAS Institute, Cary,
NC).PairedsampleandindependentStu-
dent t tests were used to compare the
within- and between-group changes re-
spectively. Primary outcome was the
change in A1C levels. The signiﬁcance of
thedifferencebetweentheA1Clevelswas
evaluated by performing ANCOVA,
which tested between-group changes
from the start to the end of study while
adjusting for baseline values. For all anal-
ysis, statistical signiﬁcance was estab-
lished at P  0.05.
RESULTS— Key demographic and
baseline clinical characteristics are sum-
marizedinTable1.Baselinedemographic
and clinical characteristics were similar.
At the 3- and 6-month follow-up periods,
the within-group change in laboratory
measurements were signiﬁcant only for
A1C, total cholesterol, and triglycerides
in the intervention group. A comparison
of between-group changes was not signif-
icant for any of the measurements except
A1C. Over the 3- and 6-month period,
A1C levels in the IBGMS group dropped
from8.81.3to8.20.91%(P0.05)
andfurtherdroppedto7.60.74%(P
0.001), respectively. The control group,
on the other hand, dropped from 8.5 
1 . 2t o8 . 3 1.1% (P  0.42) after 3
monthsbutroseto8.41.4%(P0.51)
after 6 months. Furthermore, the differ-
ence between the two groups at 6 months
postintervention was statistically signiﬁ-
cant even after adjusting for baseline A1C
levels (P  0.05).
CONCLUSIONS — Patients with di-
abetes treated with insulin are often con-
cerned about the risk of hypoglycemia
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ber of patients require communication
with their physician regarding changes in
insulin dosage to achieve stated glucose
targets. We utilized and tested an IBGMS
for communication between patients and
their endocrinologists.
In our study, patients randomized to
the intervention group had a signiﬁcant
A1C improvement after 3 months that
was sustained over 6 months. Both study
groups were provided the resources for
testing their blood glucose levels. How-
ever, the intervention group was asked to
upload their blood glucose levels and
wereremindedtotest.Intheintervention
group, the ongoing communication al-
lowed the endocrinologist to recommend
changes in the insulin dosage and regi-
men and/or patterns of testing as needed
to direct redistribution of the insulin reg-
imen. Although not statistically signiﬁ-
cant, the intervention group had a higher
increase in the average insulin dosages
after 3 months (3.5 vs. 1.7 IU) and 6
months(5.7vs.5.0IU)andmorepatients
with changes in insulin regimen (3 vs. 0).
Biweeklyencountersallowedtheendocri-
nologist to suggest small but more fre-
quent changes in insulin dosage and to
change insulin regimens when required.
We believe the ongoing communication,
patient motivation, and the ability to act
upon the results from SMBG ultimately
may have led to the signiﬁcant improve-
ment in the glucose levels.
Advantages of using an IBGMS in-
clude automatic uploading, thus remov-
ing the need for patients to keep a written
diary. In addition, the uploaded data are
analyzedanddisplayedintableandgraph
formats, giving an accurate sense of glu-
cose trends and monitoring frequency.
This can save time for the physician and
increase the accuracy of data interpreta-
tion(8).Limitationsofthesysteminclude
patient’sunwillingnessorlackofdesireto
use the Internet and the absence of a pay-
ment model for reimbursing out-of-ofﬁce
consultations.
Previously published studies involv-
ing a remote blood glucose monitoring
system have also shown improvements in
the A1C levels of type 2 diabetic patients
who used an IBGMS system compared
with control subjects (9–11). However,
these studies involved a system that in-
cluded nurses, dietitians, or an electronic
medical records system, whereas our
studywaslimitedtothepatient’sendocri-
nologist monitoring and making recom-
mendations on an IBGMS. This was not a
substitute for the patient-physician inter-
actioninaclinicalsetting;however,itsig-
niﬁcantly improved the patients’ A1C,
andovertimeweobservedgoodglycemic
control and patient satisfaction. This
method of follow-up can reduce the in-
convenience of booking appointments
solely for giving recommendations on
changes in insulin dosage and may be a
more cost-effective method of follow-up,
especiallyforruralpatientswhohavelim-
itedaccesstoadiabetesspecialist.Insum-
mary, the use of an IBGMS is an effective
method of improving glucose control.
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